Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves EFS in Patients with Resectable NSCLC
“We’ve seen tremendous scientific advancements in the treatment of non-metastatic non-small cell lung cancer in recent years, and remain committed to researching new solutions that may help even more patients achieve better long-term outcomes,” said Abderrahim Oukessou, M.D., vice president, thoracic cancers global program lead, Bristol Myers Squibb. “Taken together with the data from our CheckMate -816 trial – which led to Opdivo being the only anti-PD-1 with an approval in the neoadjuvant setting – today’s results reinforce our leadership in resectable non-small cell lung cancer and add to our legacy of transformational science in thoracic cancers. We thank the patients and investigators involved in the trial who have allowed us to advance our understanding of the importance of immunotherapy in treating patients’ cancer in earlier stages.”
Share:
More News
Thomas Guérinier, CEO and Co-founder of Inside Therapeutics: “The collaboration with OSE and MiNT provides us with a fantastic opportunity to demonstrate the uniqueness of our technology for the development of mRNA therapies from early development through to clinical trials and GMP production. The HexARN project fits perfectly with our
Thomas Mehrling, MD, PhD, CEO and Director of Helix, said “As co-founder of the Laevoroc companies, I’ve had the privilege of seeing LEUMUNA and GEMCEDA evolve from early scientific concepts into differentiated, first-in-class therapeutic candidates with real potential to transform cancer care. Their integration into Helix marks a strategic consolidation
“At Boundless, we’re committed to delivering innovative therapies for patients with oncogene-amplified cancers through disciplined execution,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “By prioritizing the novel combination of BBI-355 and BBI-825, along with our exciting Kinesin program, BBI-940, we’re concentrating our resources where we see
